29.10.2025 11:32:01 CET | Monsenso | Company Announcement

Company announcement no. 07-2025

Copenhagen, 2025.10.29

(This message includes inside information)

Monsenso now expects the revenue for 2025 to amount to DKK 9-9.5m and the EBIT to be between DKK -8m and DKK -7m. Previous guidance for the year was revenue of DKK 12-13m and EBIT DKK -7m to DKK -6m.

In connection with the half-year reporting, Monsenso announced that the company and its three local partners had been selected as the preferred vendor for a large Spanish public tender, and that the work on this project would contribute to securing growth in the second half of 2025. Meanwhile, the start of the project has been delayed and this impacts the expectations to 2025.

The annual report for 2025 will be issued on March 5, 2026.

Further information:

Monsenso

CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com 

Chairman of the board
Peter Mørch Eriksen
E-mail: Petermorcheriksen@outlook.com

Certified Adviser:

HC Andersen Capital
Bredgade 23, 
1260 København K

About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com

Attachments

• Download announcement as PDF.pdf